cigna glp-1 program is ending employee coverage for weight-loss drugs like Wegovy and Zepbound starting July 1. The decision highlights growing debates around cost, access, and the future of obesity treatment. #Cigna #GLP1 # Cigna prior authorization for Ozempic,

Patients with obesity who are at risk for low muscle mass, affecting both physical and metabolic function, may benefit from treatments that maximize fat mass reduction while preserving skeletal muscle, said Heymsfield, who is an LSU Boyd Professor and director of the Metabolism and Body Composition Laboratory

#GLP1 #Diabetes #Type2Diabetes #ObesityTreatment #OralTherapy #EliLilly #Biotech #ClinicalTrials #HealthcareInnovation #Endocrinology #CardiometabolicHealth #WeightLoss #Pharmaceuticals #InvestorInsights #PatientCare #MedTech #LifeSciences #HealthTech #Semaglutide #GLP1 #EliLilly #Wegovy #Zepbound #Ozempic #Mounjaro #NovoNordisk #Sanofi # #Orforglipron #Marshallcapps #FDA #Regulation #Pharma #Healthcare #Biotech To view or add a comment, sign in Big Breakthrough in Obesity & Metabolic Disease Treatment A new daily GLP-1 pill Orforglipron has shown remarkable weight loss and metabolic benefits in clinical trials, according to a recent publication in Nature Medicine

Healthcare earnings are largely independent of the macro environment

For the majority of GLP-1 users, digestive symptoms are part of what researchers describe as a gut adaptation phase

As long as the medication is prescribed by a licensed provider and is not on the prohibited list, the source of the medication usually does not disqualify you